Trial
NCT04066244
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Amyotrophic Lateral Sclerosis
Intervention
BLZ945
Why stopped
Study terminated after assessment of potential benefit-risk from available data
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-16